James Altucher:

OpenAI, Oracle, and SoftBank Announce Five New AI Data Center Sites, Putting Stargate Ahead of Schedule

Since Oracle’s $300 billion deal with OpenAI grabbed the headlines a few weeks ago — sending Oracle’s stock soaring and briefly making its chairman the world’s richest person — some of the biggest questions involved what the cloud computing company would do to deliver all the capacity it had promised, and how that would be financed.

Now, we’re getting more specifics: OpenAI, Oracle, and SoftBank announced late last night that they would be expanding Stargate with five new AI data center sites. Separately, Bloomberg is reporting that Oracle is looking to tap the U.S. corporate bond market for $15 billion today, which includes a 40-year offering.

The data center build-out plans put the much-hyped Stargate initiative, announced by President Trump and the companies’ leaders back in January, ahead of schedule.

Per OpenAI: “The combined capacity from these five new sites — along with our flagship site in Abilene, Texas, and ongoing projects with CoreWeave — brings Stargate to nearly 7 gigawatts of planned capacity and over $400 billion in investment over the next three years. This puts us on a clear path to securing the full $500 billion, 10-gigawatt commitment we announced in January by the end of 2025, ahead of schedule.”

⇒ Read More Here

Ray Blanco:

A Startup Used AI To Make a Psychedelic Without the Trip

Mindstate Design Labs is one of a slate of new companies aiming to make safer psychedelics by removing the classic “trip” associated with them. The company is using AI to help design psychedelic-like drugs that induce specific mental states without hallucinations, and its first compound looks promising.

Founded in 2021 and backed by Y Combinator and the founders of OpenAI, Neuralink, Instacart, Coinbase, and Twitch, Mindstate has built a set of AI models that connect biochemical data from different psychactive drugs to more than 70,000 “trip reports” compiled from a variety of sources — from official clinical trial datasets and drug forums to social media, Reddit, and even the dark web.

The platform’s analysis of how psychedelics produce different effects led to the development of its first drug candidate, MSD-001. In Phase I trial results, the drug was safe and well tolerated at five different doses in 47 healthy participants. It also produced therapeutic psychoactive effects without inducing a mind-bending trip, which the company says is a validation of its AI platform.

The company hasn’t decided on an exact indication but is considering using its therapy to treat mood disorders, compulsive disorders, and phobias.

⇒ Read More Here

Davis Wilson:

The FAA Just Fast-Tracked Flying Cars

Trump’s Transportation Secretary Sean Duffy just unveiled a plan to fast-track Advanced Air Mobility Vehicles – otherwise known as “flying cars.” Duffy’s plan is called the Electric Vertical Takeoff and Landing Integration Pilot Program.

It builds on President Trump’s executive order to unleash American drone dominance, with the goal of speeding up the rollout of next-generation Electric Vertical Takeoff and Landing (eVTOL) vehicles. 

These are aircraft that use electricity to power their multiple motors, allowing them to take off and land vertically like a helicopter. eVTOLs aims to provide quieter, cleaner, and more efficient air travel for passengers and cargo in cities.

The leading companies in this industry are still small compared to their potential market size, creating a rare opportunity for investors. They include Joby Aviation (JOBY), Archer Aviation (ACHR), Eve Air Mobility (EVEX), and Wisk Aero (owned by Boeing).

That said, many of these stocks are trading at high valuations relative to their current revenue and scale. I’m keeping a close eye on them, watching how trials progress and how regulations evolve. For now, it makes sense to wait for a more attractive entry point before investing.

Stay tuned.

⇒ Read More Here